Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Indication
As monotherapy for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option. SMC restriction: treat...
Therapeutic Area
Malignant disease and immunosuppression
Status Description
Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines
Formulation
25mg/mL concentrate for solution for infusion
Comments
November 2021 - Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.